NICE approves new ‘chemo-free’ treatment for lymphoma


  • Dawn O'Shea
  • Oncology drug update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

In draft guidance released today (26 February 2020), NICE has approved lenalidomide (Revlimid) with rituximab as an option for previously treated follicular lymphoma (grade 1 to 3A) in adults.

Lenalidomide is the first approved targeted treatment for follicular lymphoma that is not an anti-CD20 antibody.

In the phase III AUGMENT trial reported last year in the Journal of Clinical Oncology, the addition of lenalidomide to rituximab significantly prolonged progression-free survival (PFS) in patients with relapsed or refractory indolent lymphoma. After median follow-up of 28.3 months median PFS was 39.4 months with lenalidomide plus rituximab vs 14.1 months with rituximab alone (hazard ratio [HR] 0.46; P

NICE says confidential matching-adjusted indirect data presented to the appraisal committee showed an improvement in progression-free survival (PFS) and overall survival (OS) for lenalidomide with rituximab compared with R-CHOP and R-CVP. However, data on median PFS and OS are currently immature.

Although the combination of lenalidomide with rituximab costs more than rituximab with chemotherapy, the cost-effectiveness estimate is within the range that NICE normally considers an acceptable use of NHS resources.

The draft guidance is now open for public comment.